Solara Active Pharma Sciences shares jumped 14% after the pharmaceutical company posted a ₹9.6 crore net profit after tax (PAT) in the March quarter against net losses in the same period a year ago, according to the consolidated financial statements.
The NSE filings showed that the company recorded a net loss of ₹2.10 crore in the March quarter of the previous financial year.
The company's revenue from core operations surged nearly 42% to ₹387 crore in the fourth quarter of the financial year ended 2025-26, compared year-on-year with ₹273 crore in the same period a year ago.
Pharma stock, Solara shares, surged 14.5% to hit the intraday high of ₹581.75 after earnings release on Friday, compared to ₹507.70 at the previous market close, according to NSE data. The company announced its Q4 results in the afternoon market session.
The company's earnings per share (EPS) were at ₹2.2 apiece in the fourth quarter, compared with a negative ₹0.93 per share in the same period a year earlier.
Business snapshot
In the investor's presentation, the pharma company, Solara, acknowledged that the company has been witnessing ongoing headwinds in its commodity 'Ibuprofen' business as they continue to witness margin pressure.
The filings also showed that the Ibuprofen business had a gross margin of 23% in the fourth quarter, and turned in an earnings before interest, tax, depreciation and amortisation (EBITDA) margin of negative 21% in the March quarter.
On the base business level, the company has an EBITDA margin of 26%, which is a 16% YoY rise from the previous year.
"We continue to be challenged by the Ibuprofen business, which is demonstrating weak profitability, operating at a negative 21% EBITDA margin with gross margins of 23%. Given the persistent headwinds on this business, we have appointed bankers to evaluate strategic options for this business to ensure optimal long-term value creation," said Sandeep Rao, the MD and CEO of Solara Active Pharma Sciences.
Solara share price trend
Although Solara shares have lost 63% in the last five years, the company stock has delivered more than 64% returns in the last three years, and over 10% gains in the past one year period, as per NSE data.
So far in 2026, the pharma stock has risen 1.9% on a year-to-date basis and has gained 16% in the past one month. Solara shares were trading 9.2% higher over the last five market sessions.
Shares of Solara hit its 52-week high of ₹734.40 on July 25, 2025, while the 52-week low was at ₹422 on March 30, 2026, according to the exchange data. The company's market capitalisation (M-Cap) was at ₹2,097 crore as of Friday's trading session.
Disclaimer: This article is purely for informational purposes and should not be considered investment advice from Upstox. Please consult with a financial advisor before making any investment decisions.